Amyloidosis and monoclonal immunoglobulin deposition disease: From Virchow to mass spectrometry

Virtual Lecture

Expires: June 24, 2023


In this month’s “Virtual Lecture,” Lisa Rimsza, M.D., covers the history and spectrum of diseases known as “amyloidosis” presented in the context of a clinical case report published in Mayo Clinic Proceedings. The clinical presentation, detection methods, classification, prognosis, and non-amyloid immunoglobulin deposition diseases are described, including recent comprehensive mass spectrometry data from Mayo Clinic Laboratories.


Video length: 44 minutes


Lisa M. Rimsza, M.D. portrait square

Lisa Rimsza, M.D.

Professor of Laboratory Medicine and Pathology
Division of Hematopathology
Mayo Clinic, Scottsdale, Arizona 

Learning objectives

Upon completion of this activity, participants should be able to:

  • Summarize the pathogenesis of amyloidosis
  • Classify amyloidosis based on clinical presentations
  • Classify amyloidosis based on amyloid protein subtypes
  • Justify the role of mass spectrometry in management of amyloidosis
  • Compare non-amyloid deposition diseases to traditional amyloidosis

Intended audience

This program is appropriate for clinicians, pathologists, medical technologists, nurses, pharmacists, and other allied health staff.


The following types of credit are offered for this event:


Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 0.5 P.A.C.E.® contact hour.

To obtain credit

1. Watch the video.

2. Complete the posttest and evaluation that launches immediately following the video.

3. Generate and print your certificate(s).

Level of instruction for this program is intermediate.

Faculty disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Learn more about our testing


Contact us:

MCL Education (@mmledu)

MCL Education

This post was developed by our Education and Technical Publications Team.